(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...

The Pfizer settlements come as GSK, a previous Zantac manufacturer, defends itself in an ongoing trial, while Sanofi, which recalled the drug in 2019 over cancer claims, agreed to pay more than ...

After protracted legal battling, GSK has agreed to pay up to $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac ...

Oct 11 (Reuters) - GSK , opens new tab on Wednesday said it agreed to settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion. The agreements involve ...

Sanofi agreed in April to pay more than $100 million to settle about 4,000 Zantac-related lawsuits. Pfizer agreed to settle more than 10,000 related cases, Bloomberg reported in May.

Feb 29 (Reuters) - GSK , opens new tab agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series ...